Loading...
Loading...
LVTX| Name | Value |
|---|---|
| Revenues | 1.2M |
| Cost of Revenue | 0.9M |
| Gross Profit | 0.3M |
| Operating Expense | 14.8M |
| Operating I/L | -13.5M |
| Other Income/Expense | -0.3M |
| Interest Income | 0.6M |
| Pretax | -13.9M |
| Income Tax Expense | 0.1M |
| Net Income/Loss | -13.9M |
LAVA Therapeutics N.V. is a clinical-stage immuno-oncology company specializing in the development of cancer treatments. The company's Gammabody platform focuses on creating novel bispecific antibodies to harness the potency and precision of gamma delta T cells, aiming to trigger an anti-tumor immune response and improve outcomes for cancer patients. Its lead clinical-stage candidates, LAVA-051 and LAVA-1207, are in Phase 1/2a clinical trials for blood cancers and metastatic castration-resistant prostate cancer, respectively. Additionally, the company is developing other Gammabody drug candidates, including those targeting the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors and preclinical candidates for various hematologic malignancies.
